Skip to content

Released Nov 7, 2018, before the open

10-Q filed Nov 7, 2018, 38 days after period end · 0001144204-18-057990

Q3 2018 · 10-Q
Revenue$663.00K−91.2% vs Q3 2017−66.9% vs Q2 2018
Net Income-$5.32MN/M vs Q3 2017N/M vs Q2 2018
EPS Diluted-$0.40N/M vs Q3 2017N/M vs Q2 2018
Gross Profit-$1,254,000N/M
Operating Income-$3,741,000N/M
Operating Cash Flowderived$13,639,000N/M
Free Cash Flowderived$13,535,000N/M
Margins · derived
Gross margin-189.1%−208.5 pt vs Q3 2017
Operating margin-564.3%−461.1 pt vs Q3 2017
Net margin-802.7%−650.7 pt vs Q3 2017

What the release said

The release

Same quarter

MetricQ3 2018Q3 2017Q3 2016Q3 2015
Revenue$663.00K$7.53M$4.67M$1.34M
Net Income-$5.32M-$11.44M-$7.29M-$3.82M
EPS Diluted-$0.40-$0.09-$0.07-$0.04

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR